# Quarterly Activity Report and Appendix 4C for Q3 FY26

**30 April 2026**

**Highlights**

- University of Chicago Medicine, ranked among the top U.S. hospitals for Pulmonology and Lung Surgery, expanded its agreement with 4DMedical to include an initial pre-paid scan package, becoming the fifth U.S. Academic Medical Centre (AMC) to commercially adopt CT:VQ™
- Mayo Clinic, consistently ranked the number one hospital in the United States, deployed CT:VQ™ for ventilation and perfusion analysis under an initial 90-day evaluation arrangement
- Contract executed with GlaxoSmithKline (GSK), one of the world's largest pharmaceutical companies, to supply 4DMedical's quantitative lung imaging analytics in support of pulmonary drug development
- CT:VQ™ received CE Mark certification, enabling commercial deployment across the European Union, one of the world's largest respiratory imaging markets
- Coronary Artery Calcium (CAC) analysis cleared in Canada, coinciding with 4DMedical's participation at the Canadian Association of Radiologists (CAR) Annual Scientific Meeting in Montreal
- U.S. Centers for Medicare & Medicaid Services (CMS) established HCPCS code G0680, a new reimbursement pathway for AI-based opportunistic coronary calcium analysis from routine CT scans
- Completion of $150 million institutional placement at $3.80 per share in January 2026, cornerstoned by new global long-only institutional investors, with dilution to existing shareholders limited to 3.86%
- Completion of $83 million institutional placement at $5.90 per share in March 2026, limiting total dilution to 2.45%, with proceeds to fund the expansion and acceleration of CT:VQ™ into Europe while maintaining balance sheet strength
- 4DMedical included in the S&P/ASX 200 Index, effective prior to the open of trading on 20 April 2026
- Pro forma cash balance of $282.7 million as at 31 March 2026
- 4DMedical now delivering SaaS products at 477 sites globally, up 32% YoY, producing a record quarter of 86,200 scans in Q3 FY26, up 79% YoY
- Underlying SaaS revenue up 24% YTD FY26 vs pcp, with Q3 customer receipts up 18% vs pcp, reflecting strong operational momentum in advance of the impact of CT:VQ™

---

**Melbourne, Australia, 30 April 2026:** 4DMedical Limited (ASX: 4DX, "4DMedical" or the "Company"), a global leader in respiratory imaging technology, is pleased to provide its Quarterly Activity Report and Appendix 4C Cash Flow Report for the quarter ended 31 March 2026.

## Continued adoption of CT:VQ™ across leading U.S. AMCs

Q3 FY26 represented another quarter of significant commercial momentum for CT:VQ™ in the United States, building on FDA clearance and CMS reimbursement secured in September 2025. The pace of institutional adoption reflects the compelling clinical value proposition of CT:VQ™: eliminating the need for radioisotope and contrast administration, providing superior image resolution compared to nuclear medicine, integrating seamlessly into existing CT imaging workflows, and accessing established reimbursement pathways that support sustainable clinical adoption.

**University of Chicago Medicine**

In January 2026, the Company expanded its long-standing partnership with University of Chicago Medicine (UChicago Medicine) to incorporate a commercial contract for CT:VQ™. UChicago Medicine is consistently ranked among the United States' premier centres for complex lung disease. Its Interventional Pulmonology and Advanced Diagnostics programs have been early adopters of functional imaging, using 4DMedical analyses to enhance understanding of regional ventilation and to support clinical decisions in COPD, small airways disease, and pre-procedural planning.

Building on the long-standing partnership, where UChicago Medicine utilises 4DMedical's comprehensive portfolio of structural and functional lung imaging products including CT LVAS™, the expanded agreement now incorporates a commercial contract for CT:VQ™ with an initial pre-paid scan package to accelerate clinical deployment.

With UChicago Medicine's commercial adoption, CT:VQ™ has now been commercially adopted by five leading U.S. AMCs:

- Stanford University – a world leader in innovation, research and complex patient care, became the first U.S. AMC to commercially adopt CT:VQ™ under a pay-per-scan model.
- University of Miami – a nationally recognised pulmonary medicine centre.
- Cleveland Clinic – consistently ranked among the top hospitals in the U.S. and recognised globally for clinical excellence.
- UC San Diego Health – consistently ranked in the top 10 in the U.S. for pulmonology and lung surgery, integrated CT:VQ™ into its advanced cardiothoracic imaging workflow.
- University of Chicago Medicine – ranked among the top U.S. hospitals for Pulmonology and Lung Surgery, with a leading Interventional Pulmonology program.

Together, these early commercial adopters form a growing network of high-value reference sites that anchor 4DMedical's U.S. commercial strategy and drive broader market education and adoption.




**https://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview*

**Mayo Clinic**

In March 2026, Mayo Clinic (Mayo), consistently ranked the number one hospital in the United States, commenced a 90-day evaluation agreement for CT:VQ™ ventilation and perfusion analysis. The deployment enables Mayo's clinical teams to become familiar with the technology's advanced diagnostic outputs and assess its application across various clinical use cases. The evaluation at Mayo Clinic is considered significant as it aligns with 4DMedical's publicly stated strategy of expanding deployment across leading U.S. AMCs. The evaluation agreement does not constitute a commercial contract commitment, and no decision has been made regarding any ongoing or expanded use of CT:VQ™ following the evaluation period.

## The market opportunity for CT:VQ™

CT:VQ™ is the world's first and only non-contrast, CT-based ventilation-perfusion imaging technology. It measures regional lung tissue motion and local density changes to generate comprehensive ventilation and perfusion maps without requiring radiotracers or contrast agents.

CT:VQ™ addresses several critical limitations of traditional nuclear VQ imaging. It integrates seamlessly with existing CT protocols, requires no additional infrastructure or specialised equipment, and delivers superior image resolution and precise quantification, all from a routine CT scan.

Significantly, CT:VQ™ leverages the extensive installation base of approximately 14,500 CT scanners across the U.S. healthcare system. This broad accessibility extends advanced VQ imaging capabilities to rural and community healthcare facilities that may lack nuclear medicine infrastructure, democratising access to this critical diagnostic tool.

Over one million nuclear VQ scans are performed annually in the United States, with an average reimbursement rate of approximately US$1,150 per scan. This represents an addressable market of more than US$1.1 billion annually in the U.S., estimated at over US$2.6 billion globally. Given the clinical and logistical advantages of CT:VQ™ over traditional nuclear VQ imaging, 4DMedical is confident CT:VQ™ can rapidly capture a significant part of this market and, over time, displace nuclear VQ imaging entirely. Management also anticipates that the introduction of CT:VQ™ will drive long-term growth in demand for ventilation-perfusion scans beyond the traditional nuclear VQ indications.

## Strategic pharmaceutical engagement with GSK

In April 2026, 4DMedical entered a contractual engagement with GlaxoSmithKline (GSK), in association with leading imaging data platform Flywheel Exchange, to provide its proprietary quantitative lung imaging analytics in support of pulmonary drug development and clinical research.

Under the one-year agreement, which commences on 1 May 2026, 4DMedical will supply advanced lung imaging biomarkers from its software analytics platform, enabling sensitive, quantitative assessment of lung structure and function across clinical trial cohorts.

The engagement with one of the world's largest pharmaceutical companies reflects increasing adoption of 4DMedical's analytics platform by global biopharmaceutical companies seeking scalable, reproducible imaging endpoints to improve trial efficiency, patient stratification, and longitudinal disease assessment. The GSK contract builds on 4DMedical's established pharmaceutical relationships, including its ongoing engagement with AstraZeneca, and reinforces the Company's position as a preferred provider of quantitative imaging analytics for respiratory drug development.

## Regulatory milestones unlock major market opportunities

### CE Mark certification for CT:VQ™

The European Union (EU) represents a significant commercial opportunity for CT:VQ™. With a population exceeding 450 million, and a highly developed hospital-based imaging infrastructure, the EU constitutes one of the largest global markets for advanced cardiothoracic imaging.

CT is the dominant diagnostic imaging modality across European healthcare systems, supported by an extensive network of CT scanners and well-established clinical workflows. Ventilation-perfusion (VQ) imaging is routinely used for the investigation of pulmonary embolism and other cardiopulmonary

conditions in the EU, yet access to nuclear VQ imaging remains constrained in many regions due to radiotracer availability, workforce limitations, and operational complexity.

CT:VQ™ directly addresses these challenges by delivering quantitative ventilation-perfusion insights from routine non-contrast CT scans, without the need for radiotracers or specialised infrastructure. CE Mark certification enables 4DMedical to immediately engage with key healthcare providers across the EU, supporting clinical adoption, commercial rollout, and collaboration with leading respiratory centres.

Beyond the direct commercial opportunity, Europe plays a critical role in shaping global clinical practice in respiratory imaging. Many of the world's leading respiratory thought leaders, academic centres, and international congresses are based in Europe, and regulatory clearance materially enhances 4DMedical's ability to engage with these clinicians, support locally led research, and contribute to the global evidence base for CT:VQ™. In parallel, investment in Europe will increase visibility among U.S. clinicians, many of whom regularly attend European congresses and collaborate closely with European research groups.

**UKCA certification for CT:VQ™**

In April 2026, following CE Mark certification in March 2026, CT:VQ™ obtained UKCA certification for clinical use in the United Kingdom under the regulatory oversight of the Medicines and Healthcare products Regulatory Agency (MHRA). This regulatory clearance allows for the immediate commercial deployment of CT:VQ™ across both public and private healthcare providers within the UK.

The UK represents one of the world's most developed diagnostic imaging environments. Millions of chest CT scans are performed annually, with CT forming a core diagnostic tool for lung cancer screening, COPD, interstitial lung disease, pulmonary embolism, and acute care workflows. CT:VQ™ is uniquely positioned to integrate into these established pathways. Institutions such as the Royal Brompton Hospital in London, where 4DMedical clinical research is underway, are internationally recognised centres of excellence in cardiopulmonary research and clinical care.

With UKCA and CE Mark certifications now in hand, 4DMedical holds regulatory clearance for CT:VQ™ across the United States, the European Union, the United Kingdom, Canada, and New Zealand.

**CAC clearance in Canada**

4DMedical's Coronary Artery Calcium (CAC) analysis solution received regulatory clearance from Health Canada, permitting clinical use across Canadian healthcare institutions. This milestone coincided with 4DMedical's attendance at the Canadian Association of Radiologists (CAR) Annual Scientific Meeting in Montreal, where the Company presented its expanding cardiopulmonary imaging portfolio to radiologists, researchers and health system leaders.

**CAC reimbursement milestone in the U.S.**

In the United States, CMS established HCPCS code G0680, a dedicated reimbursement pathway for AI-enabled opportunistic analysis of coronary artery calcium from routine chest CT scans. The code provides reimbursement of US$15.50 per study in the hospital outpatient setting. The creation of a specific reimbursement code for AI-enabled opportunistic CAC analysis is an important market-creation event, establishing the economic infrastructure for broader clinical adoption without requiring dedicated cardiac CT imaging or additional scan time.

## Summary of 4DMedical regulatory status by product and region

The following graphic shows the regulatory status of each 4DMedical product by region:




| | FDA (USA) | CE Mark (EU) | TGA (AU) | CMDR (Canada) | MHRA (UK) | Medsafe (NZ) | ANVISA (Brazil) |
|---|---|---|---|---|---|---|---|
| CT LVAS™ | ✓ | ✓ | ✓ | ✓ | | ✓ | |
| CT:VQ™ | ✓ | ✓ | Submitted | ✓ | ✓ | ✓ | |
| IQ-UIP™ | ✓ | | | Submitted | | | |
| LDA™ | ✓ | ✓ | ✓ | ✓ | ✓ | | ✓ |
| Lung Texture | | ✓ | ✓ | ✓ | ✓ | | ✓ |
| CAC™ | ✓ | ✓ | Submitted | ✓ | | | ✓ |
| PHA™ \| RV/LV | ✓ | ✓ | ✓ | | | | ✓ |
| XV LVAS® | ✓ | ✓ | ✓ | | | ✓ | |

## Capital markets activity

### 4DMedical completes $150m institutional placement

In January 2026, the Company completed a $150 million single-tranche institutional placement at $3.80 per share, cornerstoned by new global long-only institutional investors with strong support from existing shareholders and applications multiple times the placement size. The placement comprised $79.1 million of new shares and a $70.9 million sale of existing shares previously issued to Alpha Investment Partners as collateral under a funding facility (announced 28 June 2024), with all proceeds (net of transaction costs) paid to the Company and none to Alpha. By repurposing the Alpha shares, dilution to existing shareholders was limited to 3.86%

### 4DMedical completes $83m institutional placement

In March 2026, coincident with CE Mark certification, the Company completed an $83 million single-tranche institutional placement at $5.90 per share, following significant inbound interest from institutions. The placement price represented a 6.1% discount to the last closing price and a 12.3% premium to the 5-day VWAP. The placement resulted in the issue of approximately 14.1 million shares within the Company's existing placement capacity under ASX Listing Rule 7.1, representing an increase of 2.45% in shares on issue. Proceeds will fund the commercial launch of CT:VQ™ across Europe and to maintain balance sheet strength and flexibility.

### Inclusion in the S&P/ASX 200 Index

4DMedical was included in the S&P/ASX 200 Index, effective prior to the open of trading on 20 April 2026. The S&P/ASX 200 is Australia's primary benchmark equity index, representing the largest 200 companies by

market capitalisation. Inclusion broadens 4DMedical's institutional shareholder base and increases visibility among index-tracking and passive investment funds.

The Company's inclusion in the S&P/ASX 200 reflects the significant progress achieved over the past twelve months, including FDA clearance of CT:VQ™ in September 2025; commercial CT:VQ™ adoption at five leading U.S. AMCs (Stanford, University of Miami, Cleveland Clinic, UC San Diego Health and University of Chicago Medicine), with CT:VQ™ also deployed at Mayo Clinic under a 90-day evaluation; execution of the Philips distribution agreement for CT:VQ™; CE Mark and UKCA certifications enabling access to the European Union and the United Kingdom; and growing pharmaceutical engagement with companies including AstraZeneca and GSK.

## Financial performance and cash position

The Company's pro forma cash balance as at 31 March 2026 was $282.7 million.

Underlying SaaS revenue was up 24% vs pcp for the nine months to March 2026, driven by increased penetration across B2B SaaS sites and distributors, reflecting strong operational momentum in advance of the impact of CT:VQ™.

Operating revenue for YTD FY26 was $5.0 million, up 12% vs pcp, with gross margins exceeding 90%.

Receipts from customers in Q3 FY26 increased 18% vs pcp to $1.4 million, with YTD receipts from customers increasing 15% to $4.4 million, attributable to increasing site and scan numbers and annual renewals of key client sites.

Net operating cash outflows for Q3 FY26 were ($10.2 million), with operating cash outflows down 10.3% vs pcp, as the Company continues to realise opportunities for cost optimisation to allow re-investment in growth activities.

## Operational metrics

Through 31 March 2026, 4DMedical continued to expand globally, with the Company now delivering SaaS products at 477 sites. This represents a 32% growth year-over-year (YoY) compared to 361 sites as at 31 March 2025.

In Q3 FY26, the Company produced a record 86,200 scans, up 79% YoY and a total of approximately 240,000 YTD, including structural and functional scans. This growth was driven by a significant increase across the subscription-based product portfolio as the pay-per-use client base grows and new commercial contracts initiate.






## Related Party Transactions (Listing Rule 4.7C)

Payments to related parties of $0.35 million included in Item 6 of the attached Appendix 4C Cash Flow Report were for salaries and fees paid to executive and non-executive directors during the quarter ending 31 March 2026.

## 4DMedical MD/CEO and Founder Andreas Fouras said:

*The milestones achieved this quarter demonstrate both the phenomenal pace of 4DMedical's progress and our capability to execute on our commercial strategy.*

*The operational metrics delivered this quarter demonstrate our team's capacity to win new customers, and deliver scans at real scale with our pre-CT:VQ™ products. 4DMedical is delivering over 1,300 scans per day to an incredibly sticky customer base.*

*The March quarter was also a defining period for CT:VQ™ as we accelerated the transition from regulatory milestones into scaled commercial execution. In the U.S., CT:VQ™ continued to gain traction across leading Academic Medical Centres, with University of Chicago Medicine becoming our fifth commercial AMC adopter. The deployment of CT:VQ™ at Mayo Clinic under a 90-day evaluation is also a powerful signal of clinical interest at the highest levels of healthcare.*

*At the same time, we unlocked significant new growth levers internationally. CE Mark and UKCA certifications enable near-term commercial rollout across Europe and the United Kingdom, increasing the opportunity for CT:VQ™ scans from 1 million to 1.75 million scans per year globally. Together, these approvals position CT:VQ™ and our broader platform to integrate into routine clinical workflows across multiple major healthcare systems.*

*Our engagement with GlaxoSmithKline highlights the increasing role of quantitative lung imaging in pharmaceutical research and complements our core clinical strategy. Coupled with the successful completion of two institutional placements totalling $233 million during the quarter, and our subsequent inclusion in the S&P/ASX 200 Index, we now have the balance sheet strength and market profile to invest decisively in commercial expansion, customer onboarding, and evidence generation across priority markets.*

*With strong clinical momentum, expanding reimbursement pathways, and regulatory access now in place across the U.S., Europe, the UK and other key regions, we are entering the next phase of growth with clear execution focus. Our priority over the balance of calendar 2026 is to win the battle for thought leadership in our sector, as evidenced by winning contracts with leading sites across the US. This creates a network effect and lays the foundation to powerful growth in scan volumes as we head into calendar 2027.*

*Our thought leadership strategy is already paying dividends, and at hospitals across the US excitement in CT:VQ™ is growing. Our team has built the experience to deliver across earlier generations of product. Now that these efforts are supercharged with the unique capabilities of CT:VQ™, our sales pipeline is bursting with opportunity.*

**–ENDS–**

Authorised by the 4DMedical Board of Directors.

## Contacts


**Corporate**
Investor Relations
investor.relations@4dmedical.com

**Administration**
Company Secretary
companysecretary@4dmedical.com

**Media Enquiries**
Julia Maguire
julia@thecapitalnetwork.com.au

**About 4DMedical**

4DMedical Limited (ASX:4DX) is a global medical technology company revolutionizing respiratory care with advanced imaging and artificial intelligence. Its patented **XV Technology®** transforms standard scans into rich, functional insights that allow physicians to detect, diagnose, and monitor lung disease earlier and with greater precision.

4DMedical's expanding software portfolio includes the FDA-cleared **XV Lung Ventilation Analysis Software (XV LVAS®)**, **CT LVAS™**, and the ground-breaking **CT:VQ™** solution designed to set new benchmarks in cardiothoracic imaging by combining ventilation and perfusion analysis.

Delivered seamlessly through a Software-as-a-Service (SaaS) model, 4DMedical's solutions integrate into existing hospital infrastructure, enhancing physician productivity and enabling more personalized patient care. With the addition of advanced AI capabilities from its 2023 acquisition of **Imbio**, 4DMedical continues to push the boundaries of medical imaging to redefine how respiratory disease is understood and treated worldwide.

Learn more at www.4dmedical.com

# Appendix 4C

## Quarterly cash flow report for entities subject to Listing Rule 4.7B

| Name of entity | |
|---|---|
| 4DMedical Limited | |
| **ABN** | **Quarter ended ("current quarter")** |
| 31 161 684 831 | 31 March 2026 |

| Consolidated statement of cash flows | | Current quarter $A'000 | Year to date (9 months) $A'000 |
|---|---|---|---|
| **1.** | **Cash flows used in operating activities** | | |
| 1.1 | Receipts from customers | 1,433 | 4,350 |
| 1.2 | Payments for | | |
| | research and development | (4,028) | (11,569) |
| | product manufacturing and operating costs | - | (27) |
| | advertising and marketing | (1,189) | (2,845) |
| | leased assets | (383) | (928) |
| | staff costs | (4,226) | (11,807) |
| | administration and corporate costs | (2,633) | (7,908) |
| 1.3 | Dividends received (see note 3) | - | - |
| 1.4 | Interest received | 753 | 937 |
| 1.5 | Interest and other costs of finance paid | (49) | (159) |
| 1.6 | Income taxes paid | - | - |
| 1.7 | Government grants and tax incentives (GST inclusive) | 159 | 6,629 |
| 1.8 | Other (provide details if material) | - | - |
| **1.9** | **Net used in operating activities** | **(10,163)** | **(23,327)** |

| | | | |
|---|---|---|---|
| **2.** | **Cash flows used in investing activities** | | |
| 2.1 | Payments to acquire or for: | | |
| | (a) entities | - | - |
| | businesses | - | - |
| | property, plant and equipment | (349) | (487) |
| | investments | - | - |
| | intellectual property | - | - |

| Consolidated statement of cash flows | | Current quarter $A'000 | Year to date (9 months) $A'000 |
|---|---|---|---|
| | other non-current assets | (56) | (255) |
| 2.2 | Proceeds from disposal of: | | |
| | (b) entities | - | - |
| | businesses | - | - |
| | property, plant and equipment | - | - |
| | investments | - | - |
| | intellectual property | - | - |
| | other non-current assets | - | - |
| 2.3 | Cash flows from loans to other entities | - | - |
| 2.4 | Dividends received (see note 3) | - | - |
| 2.5 | Research and development tax incentive | - | - |
| 2.6 | Capitalisation of development costs to intangible assets | - | - |
| 2.7 | Other (provide details if material) | - | - |
| **2.8** | **Net cash used in investing activities** | **(405)** | **(742)** |

| | | | |
|---|---|---|---|
| **3.** | **Cash flows from financing activities** | | |
| 3.1 | Proceeds from issues of equity securities (excluding convertible debt securities) | 150,000 | 150,000 |
| 3.2 | Proceeds from issue of convertible debt securities | - | - |
| 3.3 | Proceeds from exercise of options | 15,922 | 70,397 |
| 3.4 | Transaction costs related to issues of equity securities or convertible debt securities | (8,827) | (9,279) |
| 3.5 | Proceeds from borrowings | - | 10,000 |
| 3.6 | Repayment of borrowings | - | - |
| 3.7 | Transaction costs related to loans and borrowings | - | (111) |
| 3.8 | Dividends paid | - | - |
| 3.9 | Other | | |
| | (a) payment of lease liabilities | (279) | (807) |
| | (b) net cash paid for settlement of options | - | - |
| **3.10** | **Net cash from financing activities** | **156,816** | **220,200** |

| Consolidated statement of cash flows | | Current quarter $A'000 | Year to date (9 months) $A'000 |
|---|---|---|---|
| **4.** | **Net (decrease)/increase in cash and cash equivalents for the period** | | |
| 4.1 | Cash and cash equivalents at beginning of period | 56,762 | 6,879 |
| 4.2 | Net used in operating activities (item 1.9 above) | (10,163) | (23,327) |
| 4.3 | Net cash used in investing activities (item 2.8 above) | (405) | (742) |
| 4.4 | Net cash from financing activities (item 3.10 above) | 156,816 | 220,200 |
| 4.5 | Effect of movement in exchange rates on cash held | - | - |
| **4.6** | **Cash and cash equivalents at end of period** | **203,010** | **203,010** |

| 5. | Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts | Current quarter $A'000 | Previous quarter $A'000 |
|---|---|---|---|
| 5.1 | Bank balances | 203,010 | 56,762 |
| 5.2 | Call deposits | - | - |
| 5.3 | Bank overdrafts | - | - |
| 5.4 | Other (provide details) | - | - |
| **5.5** | **Cash and cash equivalents at end of quarter (should equal item 4.6 above)** | **203,010** | **56,762** |

| 6. | Payments to related parties of the entity and their associates | Current quarter $A'000 |
|---|---|---|
| 6.1 | Aggregate amount of payments to related parties and their associates included in item 1 | 354 |
| 6.2 | Aggregate amount of payments to related parties and their associates included in item 2 | - |

*Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.*

| 7. | **Financing facilities**<br>*Note: the term "facility' includes all forms of financing arrangements available to the entity.*<br>*Add notes as necessary for an understanding of the sources of finance available to the entity.* | **Total facility amount at quarter end $A'000** | **Amount drawn at quarter end $A'000** |
|---|---|---|---|
| 7.1 | Loan facilities | 10,000 | 10,000 |
| 7.2 | Credit standby arrangements | - | - |
| 7.3 | Other (please specify) | - | - |
| 7.4 | **Total financing facilities** | **10,000** | **10,000** |

| | | |
|---|---|---|
| 7.5 | **Unused financing facilities available at quarter end** | - |

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

AUD $10m strategic investment from Pro Medicus, as announced on the ASX 31/07/2025. Maturity – July 2027, Interest Rate – 12.5%, Secured – Yes. Refer to ASX announcement on 31/07/2025 for all material details of this debt facility.

| 8. | **Estimated cash available for future operating activities** | **$A'000** |
|---|---|---|
| 8.1 | Net cash used in operating activities (item 1.9) | (10,163) |
| 8.2 | Cash and cash equivalents at quarter end (item 4.6) | 203,010 |
| 8.3 | Unused finance facilities available at quarter end (item 7.5) | - |
| 8.4 | Total available funding (item 8.2 + item 8.3) | 203,010 |
| 8.5 | **Estimated quarters of funding available (item 8.4 divided by item 8.1)** | **20.0** |

Answer: N/A

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: N/A

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: N/A

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: N/A

*Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.*

## Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 30 April 2026

Authorised by: Board of Directors
(Name of body or officer authorising release – see note 4)

**Notes**

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.